leisure time -WSS

leisure time

author：knowledge 2025-09-30 12:10:25 - browse：8935

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： RaDonda Vaught to speak at CommonSpirit event on patient safety

knowledge

WSS

Covid isolation guidance eased by the CDC

Children’s Hospital revives plan for pedestrian bridge

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Children’s Hospital revives plan for pedestrian bridge

How to address the problem of discarded donor organs

Biotech companies concerned about China biosecurity crackdown

explore

leisure time

knowledge

The high cost of giving birth even with insurance

AstraZeneca loses challenge to Medicare drug price negotiation

Medical leaders decry Supreme Court decision on affirmative action

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

As demand for Covid shots wanes, Moderna seeks its next success

CDC advisory group OKs chikungunya vaccine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biotech companies concerned about China biosecurity crackdown

Duchenne breakthrough therapy leaves behind pioneering families

International team creates first chimeric human

focus

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Obesity now affects over 1 billion people worldwide, study finds

Cholera vaccine supplies dangerously low, outbreaks surging

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Scientists unlock the key to scar

STAT Madness 2024: Meet the contenders

hotspot

knowledge

knowledge

leisure time